by Barry101 | Jul 18, 2022 | Press Release, Uncategorized
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions Complaint...
by Barry101 | Jul 14, 2022 | Press Release, Uncategorized
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ETOCALA, Fla., July 14, 2022 — AIM ImmunoTech...
by Barry101 | Jun 21, 2022 | Press Release, Uncategorized
Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotechnologyOCALA, Fla., June 21, 2022 — AIM ImmunoTech Inc....
by Barry101 | Jun 13, 2022 | Press Release, Uncategorized
Further expansion of patent portfolio supports of the Company’s extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla., June 13, 2022 — AIM ImmunoTech Inc. (NYSE: American...
by Barry101 | May 19, 2022 | Press Release, Uncategorized
OCALA, Fla., May 19, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | May 18, 2022 | Press Release, Uncategorized
OCALA, Fla., May 18, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
